Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arena Pharmaceuticals (Nasdaq: ARNA) announced on February 15, 2021, the granting of inducement stock options for 33,885 shares and 8,475 restricted stock units (RSUs) to eleven new employees. The stock options have a seven-year term, an exercise price of $83.95 per share, and vest over four years. RSUs also vest over four years, with a similar structure for timing and conditions. These grants are made in accordance with Nasdaq Listing Rule 5635(c)(4) and are designed to encourage new hires to join Arena’s team.
- Granting of stock options and RSUs may attract talent to the company, supporting growth.
- Stock options have favorable terms, promoting long-term employee retention.
- None.
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on February 15, 2021, the Compensation Committee of its Board of Directors granted to eleven new employees inducement stock options to purchase an aggregate of 33,885 shares of its common stock and 8,475 inducement restricted stock units ("RSUs"). The inducement stock options and RSUs have a grant date and vesting commencement date of February 15, 2021 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement stock options are non-qualified stock options, have a seven-year term, have an exercise price of
About Arena Pharmaceuticals
ARENA Pharmaceuticals is a team with a singular purpose – deliver our important medicines to patients.
In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get our medicines to patients, and relentlessly execute until it’s done.
ARENA - Care More. Act Differently.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's purpose, work, understanding, ideas, and execution. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210218006022/en/
FAQ
What are the details of the stock options granted by Arena Pharmaceuticals on February 15, 2021?
What are the RSUs granted to employees by Arena Pharmaceuticals?
Why did Arena Pharmaceuticals grant inducement stock options and RSUs?